Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL
Open Access
- 13 May 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3335-3346
Abstract
Radiotherapy (RT) is central in the management of limited-stage extranodal natural killer/T-cell lymphoma (ENKTL), nasal type. Although international guidelines recommend 50 to 56 Gy, emerging data suggest that reduced-dose RT with a radiosensitizer may provide comparable control with less toxicity. We evaluated the long-term outcomes of 40 Gy concurrent chemoradiotherapy (CCRT) followed by systemic chemotherapy. We retrospectively analyzed 155 patients newly diagnosed with limited-stage ENKTL treated at Samsung Medical Center between 2000 and 2023. All patients received 40 Gy in RT in 20 fractions with weekly cisplatin (30 mg/m2), followed by systemic chemotherapy. Clinical characteristics, treatment response, survival outcomes, and relapse patterns were assessed. The median age was 50 years, and 64.5% were male. Most patients (73.5%) had nasal-type disease, whereas 20.0% had combined nasal and nonnasal upper aerodigestive tract involvement. At a median follow-up of 73 months, the 5-year progression-free survival (PFS) and overall survival rates were 68.0% and 82.2%, respectively. Pretreatment Epstein-Barr virus DNA positivity correlated with inferior PFS (P = .043). Patients receiving CCRT plus chemotherapy had better PFS than those receiving CCRT alone (P = .004). Relapses occurred in 54 (34.8%) patients, predominantly at extranodal distant sites (21.3%), whereas the local control rate remained high (86.5%). Secondary malignancies developed in 3 patients. Median 22-item sinonasal outcome test score was 8, indicating minimal sinonasal symptom burden. A 40 Gy CCRT regimen followed by systemic chemotherapy achieved durable local control and favorable long-term survival in limited-stage ENKTL. The predominance of distant, rather than regional, relapse supports the feasibility of this reduced-dose CCRT strategy combined with systemic therapy.Keywords
This publication has 35 references indexed in Scilit:
- Safety of low-dose radiotherapy in newly diagnosed stage I/II extranodal NK/T-cell lymphoma: a single-center retrospective analysisAnnals of Hematology, 2025
- Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?Advances in Radiation Oncology, 2024
- Phase 2 Clinical Trial of Simultaneous Boost Intensity Modulated Radiation Therapy With 3 Dose Gradients in Patients With Stage I-II Nasal Type Natural Killer/T-Cell Lymphoma: Long-Term Outcomes of Survival and Quality of LifeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell LymphomaJAMA Oncology, 2017
- Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal typeEuropean Journal of Cancer, 2015
- Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal TypeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II studyAnnals of Hematology, 2014
- Early or Up-Front Radiotherapy Improved Survival of Localized Extranodal NK/T-Cell Lymphoma, Nasal-Type in the Upper Aerodigestive TractInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modalityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002